Figure 5.

Hypothetical changes in the monoclonal protein markers of patients with SMM over time. While there are multiple possible trajectories that a patient's biomarkers may take, this figure is meant to illustrate that patients may have steady increases in the tumor burden, whereas other patients have a rapidly “evolving” presentation. Patients in “trajectory B,” with rapidly increasing biomarkers, should be considered for early therapeutic intervention.